Aviron FluMist Annual Release Tests In Human Subjects May Be Required
Executive Summary
FDA may require Aviron to conduct release tests in human subjects to ensure attenuation of FluMist before each flu season, the company indicated.
You may also be interested in...
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
MedImmune should conduct head-to-head comparisons of its live intranasal flu vaccine FluMist and the marketed trivalent inactivated vaccine, FDA's Vaccine & Related Biological Drug Products Advisory Committee suggested Dec. 17
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
MedImmune should conduct head-to-head comparisons of its live intranasal flu vaccine FluMist and the marketed trivalent inactivated vaccine, FDA's Vaccine & Related Biological Drug Products Advisory Committee suggested Dec. 17
Kaiser FluMist Safety Data Analysis To Be Submitted To FDA By Year-End
Aviron expects to submit to FDA the full analysis of a FluMist pediatric safety study conducted at Kaiser Permanente outpatient clinics by the end of the year.